LNP Characterization and Analytical Development Summit on September 12-14, 2023 in Boston, United States

Recent breakthroughs from Verve Therapeutics, Vertex-Arbor Bio, and Mana.bio have propelled the field of LNP technology forward at lightning speed beyond mRNA vaccines. LNP-based therapies are now being developed for base editing, in vivo gene therapies, and RNA and DNA deliveries to treat a wide range of diseases.

However, with the updated nanomedicine guidance from the FDA and the push towards precision medicine, the growing complexity of these therapies requires drug developers and manufacturers to fine-tune and enhance their characterization and analytical capabilities in order to speed up the next generation of therapeutics to market.

Building on our LNP community, the LNP Characterization and Analytical Development Summit is the definitive forum to discuss the roadmap of characterization and bioanalysis, reference materials, and potency assays throughout the product lifecycle. This summit brings together over 80 industry experts to advance the field of LNP technology and enhance LNP characterization, bioanalytics, and assay development capabilities.

Join Merck, Moderna, Pfizer and more to fingerprint the roadmap of characterization and bioanalysis, reference materials and potency assays throughout your product lifecycle. Supercharge your knowledge and skills to propel the therapeutic potential of LNP delivery vehicles in 2024 and beyond and make a significant impact in your field!

Early bookings and group discounts available - visit the website for more information.

URLs:

Tickets: https://go.evvnt.com/1739155-2?pid=10008

Brochure: https://go.evvnt.com/1739155-3?pid=10008

Time: 08:45 - 15:45

Prices:

Conference Only - Drug Developer: USD 2099.00,

Conference Only - Solution Provider: USD 2799.00

Speakers: David Foley, Director - Analytical Research and Development, Merck, Jeremie Parot, Research Scientist, SINTEF, Le Meng, Associate Director, Hopewell Therapeutics, Noora Chaar, Principal Research Associate, Analytical Development, Moderna, Zheng Meng, Senior Director - Analytical Development and Chemistry, Manufacturing and Controls, Ultragenyx, Zichuan Zhang, Director - Analytical Development, Beam Therapeutics , Qin Zou, Group Leader and Associate Research Fellow, Pfizer, Chris Broomell, Director - Drug and Product Analytical Development, Omega Therapeutics , Michael Munson, Senior Scientist, AstraZeneca, Jennifer Wendelken, Senior Manager - Analytical Development, Editas Medicine, Marina Dobrovolskaia, Director and Head of Immunology, Operations and Nanotechnology Characterization, Frederick National Laboratory for Cancer Research